This study is in progress, not accepting new patients

Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis

Eligibility: for people ages 18 years and up (full criteria)
Location: at UCSD
Dates: study started August 2019
completion around July 2026

Description

Summary

The main purpose of this study is to characterize the long-term safety and efficacy of the drug Deucravacitinib (BMS-986165) in patients who have been previously enrolled in an applicable Phase 3 psoriasis study.

Official Title

An Open-Label, Multi-Center Extension Study to Characterize the Long-Term Safety and Efficacy of BMS-986165 in Subjects With Moderate-to-Severe Plaque Psoriasis

Keywords

Psoriasis, Deucravacitinib, BMS-986165

Eligibility

You can join if…

Open to people ages 18 years and up

Completion of the protocol-required treatment period in an applicable study of BMS-986165 in moderate-to-severe psoriasis
Women must not be pregnant, lactating, or breastfeeding

You CAN'T join if...

Any disease or medical condition that the investigator feels that would make the patient unsuitable for this study.
To be eligible for the study, a participant must not have active signs or symptoms of tuberculosis (TB) as judged by the investigator.

Other protocol-defined inclusion/exclusion criteria apply

Locations

University of California San Diego Health Systems
San Diego California 92122 United States
Local Institution - 0017
Irvine California 92697 United States
Clinical Science Institute
Santa Monica California 90404 United States
Local Institution - 0042
Sherman Oaks California 91403 United States
Dermatology Research Associates - Los Angeles
Los Angeles California 90045-3606 United States
First OC Dermatology & Belle-Aimee Skincare Clinic Fountain Valley
Fountain Valley California 92708 United States
Local Institution - 0206
Fresno California 93720 United States
Therapeutics Clinical Research
San Diego California 92123 United States
University Dermatology Group
San Diego California 92123 United States
Local Institution - 0236
Los Angeles California 90057 United States

Details

Status: in progress, not accepting new patients
Start Date: August 2019
Completion Date: July 2026 (estimated)
Sponsor: Bristol-Myers Squibb
Links: BMS Clinical Trial Information BMS Clinical Trial Patient Recruiting FDA Safety Alerts and Recalls
ID: NCT04036435
Phase: Phase 3 Psoriasis Research Study
Study Type: Interventional
Participants: About 1452 people participating
Last Updated: September 2023